ORIGINAL RESEARCH article
Front. Immunol.
Sec. Cancer Immunity and Immunotherapy
Volume 16 - 2025 | doi: 10.3389/fimmu.2025.1607098
This article is part of the Research TopicImmune Predictive and Prognostic Biomarkers in Immuno-Oncology: Refining the Immunological Landscape of CancerView all 32 articles
Exploring of bladder cancer immune-related genes and potential therapeutic targets based on transcriptomic data and Mendelian randomisation analysis
Provisionally accepted- 1Department of Urinary Surgery, Anning First People's Hospital Affiliated to Kunming University of Science and Technology, Kunming, Yunnan Province, China
- 2Faculty of Life Science and Technology, Kunming University of Science and Technology, Kunming, Yunnan Province, China
Select one of your emails
You have multiple emails registered with Frontiers:
Notify me on publication
Please enter your email address:
If you already have an account, please login
You don't have a Frontiers account ? You can register here
Background: Despite advancements in clinical treatment modalities, immune-related molecular mechanisms underlying bladder cancer remain unclear. Therefore, this study aimed to identify immune-related biomarkers and potential therapeutic targets for bladder cancer, thereby contributing to the development of novel therapeutic interventions.By integrating data from The Cancer Genome Atlas (TCGA), Gene Expression Omnibus (GEO), and genome-wide association study (GWAS) databases, combined with differential expression analysis, weighted gene co-expression network analysis (WGCNA), and Mendelian randomization analysis, key immune-related genes in bladder cancer were identified. The correlation between these key genes and immune cell infiltration was also analyzed. The diagnostic efficacy of the key genes was evaluated using Receiver Operating Characteristic (ROC) curves and validated using independent public datasets. Finally, Quantitative real-time polymerase chain reaction (qRT-PCR) was performed to confirm the potential value of these molecular markers in bladder cancer.Results: Differential expression analysis revealed 2,033 bladder cancer-related genes. WGCNA identified 1,391 immune-related genes and Mendelian randomization analysis identified 187 candidate genes with causal relationships. Eight significantly downregulated genes were identified: LIMS2, TP53INP2, IRAK3, STX2, CYP27A1, IL11RA, KCNMB1, and PDLM7. These genes were significantly associated with immune cell infiltration and exhibited good diagnostic efficacy, as demonstrated by ROC curve analysis and validated in independent public datasets. Furthermore, qRT-PCR experiments showed that LIMS2, IRAK3, STX2, IL11RA, KCNMB1, and PDLM7 were significantly downregulated in the tumor group, consistent with the bioinformatic analysis results, suggesting their potential clinical value.This study identified six immunoregulatory genes that were significantly negatively associated with bladder cancer risk. These genes may serve not only as potential biomarkers for bladder cancer immunity but also contribute to a deeper understanding of the molecular mechanisms of bladder cancer.
Keywords: Bladder cancer, Mendelian Randomization Analysis, WGCNA, CIBERSORT, biomarkers, potential therapeutic targets
Received: 07 Apr 2025; Accepted: 04 Jul 2025.
Copyright: © 2025 Xu, Yang, Ma, Tao, He, Wu, Zhao, Niu and Wang. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
* Correspondence: Lijun Wang, Department of Urinary Surgery, Anning First People's Hospital Affiliated to Kunming University of Science and Technology, Kunming, Yunnan Province, China
Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.